Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2024-05-29 Investor Presentation
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene Presentation to Bell Potter Conference 28 pages 2.2MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Imugene Limited at the Bell Potter Emerging Leaders Conference in May 2024. It includes extensive information about the company's clinical programs, pipeline, market capitalization, clinical trial designs, partnerships, and scientific data. The content is structured as a slide presentation with investment highlights, clinical data, and future plans. There is no indication that this is a formal regulatory filing such as an annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a voting result or director dealing. The document is clearly intended for investors and stakeholders to provide a comprehensive overview of the company's strategy, clinical progress, and market positioning. This matches the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2024-05-29 English
Application for quotation of securities - IMU 8 pages 20.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and contains detailed information about securities issued, transferred, or re-classified due to options being exercised or convertible securities being converted. It includes specifics such as the number of securities, issue dates, issue prices, and the resulting issued capital. The document is a formal application to the ASX for quotation of these securities, which aligns with announcements related to new share issues or capital changes. There is no indication that this is a full financial report, earnings release, or management discussion. The document is not a report publication announcement but a regulatory filing related to capital changes. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (7020 characters) supports it being a substantive announcement rather than a brief notice.
2024-05-05 English
Quarterly Activities/Appendix 4C Cash Flow Report 13 pages 595.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities & Appendix 4C Cash Report' for the quarter ended 31 March 2024, which is a clear indication of a quarterly report. It includes detailed clinical trial updates, corporate updates, financials including cash flow statements, and operational highlights. The presence of an Appendix 4C cash flow report, which is a standard quarterly cash flow report required by the ASX Listing Rules, confirms this is a comprehensive quarterly financial and operational report. The document length is substantial (15,000 characters), and it contains actual financial data and substantive analysis, not just an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2024-04-29 English
Change of Director's Interest Notice - PH 2 pages 6.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director and related parties, including dates, number of shares disposed, and nature of the transactions. This type of document is a regulatory filing specifically reporting insider transactions by directors. It is not a financial report, earnings release, or management information. It fits the definition of 'Director's Dealing' which reports personal share transactions by company directors and executives (insider trades). The document length is under 5,000 characters and contains detailed transaction data, confirming it is the actual report, not just an announcement. Therefore, the correct classification is DIRS with high confidence.
2024-04-22 English
Notification regarding unquoted securities - IMU 9 pages 24.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and contains detailed information about the issuance of unquoted securities under an employee incentive scheme by Imugene Limited. It includes specifics such as security codes, number of securities issued, issue dates, and mentions key management personnel involved. The document is a formal notification to the ASX regarding securities issuance, which aligns with announcements about share issues or capital changes. There is no indication that this is a full financial report, audit, or management discussion. The document is not a report publication announcement but a substantive notification of capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (8536 characters) supports it being a full notification rather than a brief announcement or certification.
2024-04-18 English
Imugene & Kincell Bio Strategic Partnership Investor Webinar 2 pages 151.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about an upcoming investor webinar discussing a strategic partnership. It includes details on the webinar date, presenters, registration link, and contact information. There is no financial data, report content, or detailed presentation material included. The document is short (3563 characters) and serves as a notice or invitation rather than a full investor presentation or report. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2024-04-16 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.